J Clin Oncol: The efficacy of abiraterone acetate in patients with castration resistance and androgen receptor expression salivary gland cancer (SGC)

Salivary ductal carcinoma (SDC) has similar morphological and molecular characteristics to high-grade ductal carcinoma of breast, manifested by androgen receptor (AR) expression; TP53 mutation [55%], HRAS mutation [23%], and PIK3CA mutation [23%]; and ERBB2 amplification [35%]

Salivary ductal carcinoma (SDC) has similar morphological and molecular characteristics to high-grade ductal carcinoma of breast, manifested by androgen receptor (AR) expression; TP53 mutation [55%], HRAS mutation [23%], and PIK3CA mutation [23%]; and ERBB2 amplification [35%]

The study is a single-center phase II study, and the primary endpoint is objective response rate (ORR)

The study is a single-center phase II study, and the primary endpoint is objective response rate (ORR)

From March 2015 to November 2019, 24 patients (23 men) were included in the study

The ORR was 21%, and the median DoR was 5.

The median progression-free survival was 3.

92% of patients reported at least one adverse reaction (22 cases)

Adverse events

In summary, studies have shown that abiraterone combined with luteinizing hormone releasing hormone agonist is an effective and safe second-line treatment for patients with castration resistance and androgen receptor expression salivary gland cancer (SGC)

In summary, studies have shown that abiraterone combined with luteinizing hormone releasing hormone agonist is an effective and safe second-line treatment for patients with castration resistance and androgen receptor expression salivary gland cancer (SGC)
.
Studies have shown that abiraterone combined with luteinizing hormone releasing hormone agonist is an effective and safe second-line treatment for patients with castration resistance and androgen receptor expression salivary gland cancer (SGC)
.
Studies have shown that abiraterone combined with luteinizing hormone releasing hormone agonist is an effective and safe second-line treatment for patients with castration resistance and androgen receptor expression salivary gland cancer (SGC)
.

Original source:

Original source:

Locati LD, Cavalieri S, Bergamini C, Resteghini C, Colombo E, Calareso G, Mariani L, Quattrone P, Alfieri S, Bossi P, Platini F, Capone I, Licitra L.
Abiraterone Acetate in Patients With Castration-Resistant, Androgen Receptor -Expressing Salivary Gland Cancer: A Phase II Trial.
J Clin Oncol.
2021 Oct 1:JCO2100468.
doi: 10.
1200/JCO.
21.
00468.
Epub ahead of print.
PMID: 34597119.

Locati LD, Cavalieri S, Bergamini C, Resteghini C, Colombo E, Calareso G, Mariani L, Quattrone P, Alfieri S, Bossi P, Platini F, Capone I, Licitra L.
Abiraterone Acetate in Patients With Castration-Resistant, Androgen Receptor -Expressing Salivary Gland Cancer: A Phase II Trial.
J Clin Oncol.
2021 Oct 1:JCO2100468.
doi: 10.
1200/JCO.
21.
00468.
Epub ahead of print.
PMID: 34597119.


Leave a message here